# EDGAR Filing Document

**Accession Number:** 0000728387
**File Stem:** 0001193125-26-216777
**Filing Date:** 2026-5
**Character Count:** 29909
**Document Hash:** 2fce8db03b7ec4a3e337677c9c5d9a2f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-216777.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001193125-26-216777

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 68

**CONFORMED PERIOD OF REPORT**: 20260511

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Perspective Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000728387
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411458152
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33407
- **FILM NUMBER:** 26963298

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-676-0900

**MAIL ADDRESS:**
- **STREET 1:** 2401 ELLIOTT AVENUE
- **STREET 2:** SUITE 320
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Isoray, Inc.
- **DATE OF NAME CHANGE:** 20181231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IsoRay, Inc.
- **DATE OF NAME CHANGE:** 20050805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CENTURY PARK PICTURES CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 11, 2026<br>

------

Perspective Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-33407 | 41-1458152 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| c/o Perspective Therapeutics, Inc.<br>2401 Elliott Avenue<br>Suite 320 |  |  |
| Seattle**,** Washington |  | 98121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (206) 676-0900<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | CATX | NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 2.02 Results of Operations and Financial Condition.
On May 11, 2026, Perspective Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Form 8-K") and is incorporated by reference into this Item 2.02.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

Also on May 11, 2026, the Company posted an updated corporate presentation on its website at www.perspectivetherapeutics.com. A copy of the presentation is filed as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

---

| | |
|:---|:---|
| 99.1 | [<u>Press release issued by Perspective Therapeutics, Inc., dated May 11, 2026</u>](catx-ex99_1.htm). |
| 99.2 | [<u>Corporate presentation</u>](catx-ex99_2.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PERSPECTIVE THERAPEUTICS, INC.** |
| Date: | May 11, 2026 | By:  | /s/ Joel Sendek |
|  |  |  | Joel Sendek<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![img236230851_0.jpg](img236230851_0.jpg)

**Perspective Therapeutics Provides Recent Business Highlights and <br>Reports 1Q 2026 Results**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Three clinical-stage oncology programs advancing across neuroendocrine tumors, melanoma and FAP-positive solid tumors with multiple clinical catalysts expected in 2026 across VMT-α-NET, VMT01 and PSV359 programs; lead program, VMT-α-NET, advancing toward a registration-enabling study*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Regional manufacturing network designed to support reliable supply of ready-to-administer radiopharmaceuticals for clinical development and potential commercialization; Chicago site expected to complete construction in 2026*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Cash runway expected into late 2027 to support planned clinical milestones and operational investments; cash, cash equivalents, and short-term investments of approximately $271M as of March 31, 2026*

SEATTLE – May 11, 2026 – Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2026.

"The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position," said Thijs Spoor, Perspective's CEO. "Our focus on engineering the alpha advantage across every part of the radiopharmaceutical value chain - from the radioisotope to optimized structural chemistry, theranostic processes, and regional manufacturing - differentiates Perspective, and we look forward to providing clinical and manufacturing updates throughout 2026."

**<u>Clinical Highlights</u>**

**<u>VMT-</u>*<u>α</u>*<u>-NET</u>**

We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier NCT05636618) of [<sup>212</sup>Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Updated interim data from the study, as of a data cut-off (DCO) date of March 4, 2026, were presented at the American Association for Cancer Research Annual Meeting 2026 in April 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As of April 30, 2026, the first 23 patients in Cohort 2 have had the opportunity for at least 60 weeks of follow-up since beginning treatment. By late 2026, all 46 patients in Cohort 2 will have had the opportunity for at least 60 weeks of follow-up since beginning treatment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We believe our clinical data package positions us for meaningful regulatory engagement in 2026 to align on the path forward.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As of April 30, 2026, a total of 20 patients have been treated in Cohort 3. This cohort is now closed to enrollment. By late 2026, the eight patients initially enrolled for dose-limiting toxicity (DLT) assessment will have had the opportunity for at least 48 weeks of follow-up since beginning treatment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Cohort 4 is now open for recruitment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•During the dose-finding phase of the study, we enrolled primarily NET patients whose disease originated in the pancreas or the digestive tract. We have an allowance for enrollment of NET patients whose disease originated in the lung (of which small cell lung cancer is a subset), pheochromocytoma/paraganglioma NETs, and SSTR2+ meningioma.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•We opened a proof-of-concept cohort of meningioma patients. To date, there is no approved systematic therapy for this disease. The unmet medical need may support an expedited development path.

**<u>VMT01</u>**

VMT01 is an MC1R-targeted RPT that can be radiolabeled with either <sup>203</sup>Pb for patient selection and dosimetry assessment or <sup>212</sup>Pb for alpha-particle therapy. We are conducting a multi-center, open-label, dose-finding study (clinicaltrials.gov identifier <u>NCT05655312</u>) in heavily pre-treated patients with histologically confirmed melanoma and MC1R-positive imaging scans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Since dosing re-opened for 3.0 mCi of VMT01 as monotherapy, and was initiated for 3.0 mCi of VMT01 in combination with nivolumab in September 2025, 10 patients had received VMT01 3.0 mCi treatment as of February 28, 2026; six patients had received VMT01 at 3.0 mCi in combination with nivolumab, and four patients had received 3.0 mCi of VMT01 as monotherapy, in addition to the three patients who received this monotherapy dose in late 2023. Both cohorts are now closed for enrollment.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•By late 2026, the 10 patients who had received VMT01 3.0 mCi treatment since the initiation or re-opening of these cohorts in September 2025 will have had the opportunity for at least 24 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to three doses every eight weeks).

**<u>PSV359</u>**

We designed PSV359 to target and deliver <sup>212</sup>Pb to tumor sites expressing fibroblast activation protein-α (FAP-α), which is associated with multiple highly prevalent solid tumors, in patients in need of additional treatment options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As of April 30, 2026, two patients in Cohort 1 had been treated with [<sup>212</sup>Pb]PSV359 at 2.5 mCi, and seven patients in Cohort 2 had been treated at 5.0 mCi, for a total of nine patients. By late 2026, these patients will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to have completed at least one scan after the full course of treatment (up to four doses every eight weeks).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Cohort 3 is now open for recruitment.

**<u>Updates to the preclinical pipeline</u>**

Our discovery team is preparing additional novel constructs for potential first-in-human (FIH) imaging.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In May 2026, we presented an FIH image for PSV594, designed to target and deliver <sup>212</sup>Pb to tumor sites expressing the Cholecystokinin 2 Receptor (CCK2R), which is expressed across a range of hard-to-treat cancers. The targeting moiety may also be radiolabeled with <sup>203</sup>Pb or <sup>68</sup>Ga to detect CCK2R expression in-vivo. Preclinical and FIH images suggest the targeting moiety has clean, precise tumor uptake with limited kidney retention, which may result in a desirable therapeutic index.

**<u>Updates on manufacturing infrastructure</u>**

We continue to make progress on expanding our manufacturing capabilities by increasing and enhancing capacity at existing facilities and building out recently acquired sites.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Our flagship site in the Chicago area is on track to complete construction this year. We are building a complementary site in the Los Angeles area and have plans beyond our current footprint.

------

**<u>First Quarter 2026 Financial Summary</u>**

**Cash, cash equivalents, and short-term investments** as of March 31, 2026, were approximately $271 million as compared to $145 million as of December 31, 2025. In February 2026, we announced the closing of an underwritten offering of securities with net proceeds of approximately $164 million after deducting underwriting discounts and commissions and other offering-related expenses. We believe our cash, cash equivalents, and short-term investments as of March 31, 2026, will be sufficient to fund our current clinical milestones and operational investments into late 2027.

As of March 31, 2026, we had approximately 114.0 million shares of common stock and approximately 20.5 million warrants and options to purchase shares of common stock outstanding. In connection with the February 2026 underwritten offering of securities noted above, we issued 39.6 million shares of common stock along with pre-funded warrants to purchase 6.6 million shares of common stock.

**Research and development expenses** were $21.4 million for the three months ended March 31, 2026, compared to $14.3 million for the three months ended March 31, 2025, an increase of approximately 50%. The increase in research and development expenses was primarily related to higher personnel costs, including share-based compensation, due to additional headcount to support our ongoing clinical trials, as well as increased spending on contract development and manufacturing organizations, clinical site activities, drug programs and delivery, pipeline studies and consulting.

**General and administrative expenses** were $7.0 million for the three months ended March 31, 2026, compared to $7.8 million for the three months ended March 31, 2025, a decrease of approximately 10%. The decrease in general and administrative expenses was primarily due to decreased fees for professional and consulting services and fees related to operating as a public company, partially offset by increased personnel costs.

**Net loss** for the three months ended March 31, 2026, was $26.2 million, or $0.25 per basic and diluted share, compared to a net loss of $18.2 million, or $0.25 per basic and diluted share, for the same period in 2025. During the three months ended March 31, 2026 and 2025, there was a net benefit of $2.1 million and $2.3 million, respectively, in net interest income and other expenses. In addition, during the three months ended March 31, 2025 we recognized $1.4 million of Deferred Income, which was received in 2024.

------

**About Perspective Therapeutics, Inc.**

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary <sup>224</sup>Ra/<sup>212</sup>Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

**Safe Harbor Statement**

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's expectations regarding cash runway; the Company's manufacturing, distribution and commercialization plans and capabilities; the Company's clinical and preclinical development plans and the expected timing for the release of additional data from its development programs; the Company's beliefs that its product candidates address certain unmet medical needs; the Company's expectations regarding regulatory pathways for its product candidates, the Company's interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.

------

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company's preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company's product candidates and clinical development plans; and risks related to the sufficiency of the Company's cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**Media and Investor Relations Contact:**

**Perspective Therapeutics IR:**

Annie J. Cheng, CFA

<u>ir@perspectivetherapeutics.com</u>

**ENTENTE Network of Companies**

Virginia Amann

virginiaamann@ententeinc.com

------

**Perspective Therapeutics, Inc. and Subsidiaries**

**Condensed Consolidated Balance Sheets**

**(In thousands, except shares and par value data)**

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
|  | **2026** | **2025** |
|  | **(unaudited)** |  |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $53972 | $30629 |
| &nbsp;&nbsp;Short-term investments | 216957 | 114108 |
| &nbsp;&nbsp;Accounts receivable, net (allowance for doubtful accounts was $375 for each period) | 58 | 6 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 4365 | 3646 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 275352 | 148389 |
| Noncurrent assets: |  |  |
| &nbsp;&nbsp;Property and equipment, net | 92483 | 76597 |
| &nbsp;&nbsp;Right of use asset, net | 2444 | 1500 |
| &nbsp;&nbsp;Intangible assets, in-process research and development | 40000 | 40000 |
| &nbsp;&nbsp;Other assets, net | 490 | 486 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | 410769 | 266972 |
| **LIABILITIES AND STOCKHOLDERSʼ EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable and accrued expenses | $26485 | $20511 |
| &nbsp;&nbsp;Lease liability | 1069 | 623 |
| &nbsp;&nbsp;Accrued personnel expenses | 3876 | 7489 |
| &nbsp;&nbsp;Note payable | 56 | 56 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 31486 | 28679 |
| Noncurrent liabilities: |  |  |
| &nbsp;&nbsp;Lease liability, net of current portion | 1552 | 1005 |
| &nbsp;&nbsp;Note payable, net of current portion | 1554 | 1569 |
| &nbsp;&nbsp;Deferred Income | 26600 | 26600 |
| &nbsp;&nbsp;Deferred tax liability | 1702 | 1702 |
| &nbsp;&nbsp;Other noncurrent liabilities | 437 | 386 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 63331 | 59941 |
| Commitments and contingencies |  |  |
| Stockholdersʼ equity: |  |  |
| &nbsp;&nbsp;Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | - | - |
| &nbsp;&nbsp;Common stock: $0.001 par value; 750,000,000 shares authorized; 114,017,755 and 74,337,990 shares issued | 114 | 74 |
| &nbsp;&nbsp;Additional paid-in capital | 708579 | 541687 |
| &nbsp;&nbsp;Accumulated other comprehensive (loss) income | (226) | 110 |
| &nbsp;&nbsp;Accumulated deficit | (361029) | (334840) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholdersʼ equity | 347438 | 207031 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholdersʼ equity | $410769 | $266972 |

---

------

**Perspective Therapeutics, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)**

**(Dollars and shares in thousands, except for per-share amounts)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Grant revenue | $76 | $342 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;Research and development | 21372 | 14332 |
| &nbsp;&nbsp;General and administrative | 6985 | 7842 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 28357 | 22174 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating loss | (28281) | (21832) |
| Non-operating income (expense): |  |  |
| &nbsp;&nbsp;Interest income | 2197 | 2384 |
| &nbsp;&nbsp;Interest and other expense | (105) | (128) |
| &nbsp;&nbsp;Other income from a related party | - | 1400 |
| &nbsp;&nbsp;Equity in loss of affiliate | - | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total non-operating income, net | 2092 | 3655 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(26189) | $(18177) |
| &nbsp;&nbsp;Basic and diluted loss per share | $(0.25) | $(0.25) |
| Weighted average shares used in computing net loss per share: |  |  |
| &nbsp;&nbsp;Basic and diluted | 103604 | 72357 |
| Unrealized (loss) gain on available-for-sale securities | $(336) | $70 |
| &nbsp;&nbsp;Comprehensive loss | $(26525) | $(18107) |

---

------

## Exhibit 99.2

![Slide 1](catx-ex99_2s1.jpg)

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

------

![Slide 2](catx-ex99_2s2.jpg)

------

![Slide 3](catx-ex99_2s3.jpg)

Engineering the Alpha Advantage in Targeted Oncology

------

![Slide 4](catx-ex99_2s4.jpg)

Unlocking New Treatment Options Across Solid Tumors:

------

![Slide 5](catx-ex99_2s5.jpg)

Optimizing the Entire System

------

![Slide 6](catx-ex99_2s6.jpg)

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

------

![Slide 7](catx-ex99_2s7.jpg)

Optimizing Structural Chemistry:

------

![Slide 8](catx-ex99_2s8.jpg)

Choosing The Right Isotope

------

![Slide 9](catx-ex99_2s9.jpg)

Not All ²¹²Pb Programs Are Created Equal

------

![Slide 10](catx-ex99_2s10.jpg)

------

![Slide 11](catx-ex99_2s11.jpg)

Advancing a Theranostic Approach:

------

![Slide 12](catx-ex99_2s12.jpg)

Solid Tumors are an Attractive Market for Radiopharmaceuticals

------

![Slide 13](catx-ex99_2s13.jpg)

Expanding the Addressable Market

------

![Slide 14](catx-ex99_2s14.jpg)

Direct-to-Hospital Delivery through Integrated Isotope Production

------

![Slide 15](catx-ex99_2s15.jpg)

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

------

![Slide 16](catx-ex99_2s16.jpg)

Reaching the Largest Addressable Market with Regional Manufacturing

------

![Slide 17](catx-ex99_2s17.jpg)

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

------

![Slide 18](catx-ex99_2s18.jpg)

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

------

![Slide 19](catx-ex99_2s19.jpg)

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

------

![Slide 20](catx-ex99_2s20.jpg)

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

------

![Slide 21](catx-ex99_2s21.jpg)

VMT-⍺-NET: Baseline Patient Characteristics in AACR 2026 Data Analysis

------

![Slide 22](catx-ex99_2s22.jpg)

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AACR 2026 Data Analysis

------

![Slide 23](catx-ex99_2s23.jpg)

VMT-α-NET Responses Deepen Over Time

------

![Slide 24](catx-ex99_2s24.jpg)

VMT-⍺-NET: Durable Disease Control Across All Doses

------

![Slide 25](catx-ex99_2s25.jpg)

Spider Plot of Tumor Change Over Time by Patient

------

![Slide 26](catx-ex99_2s26.jpg)

Best-in-class Safety Profile1

------

![Slide 27](catx-ex99_2s27.jpg)

Blood Creatinine During Follow-up for All Patients Treated (n=64)

------

![Slide 28](catx-ex99_2s28.jpg)

VMT-α-NET's Compelling Profile Supports Potential Registration Study at Current Dose Level

------

![Slide 29](catx-ex99_2s29.jpg)

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

------

![Slide 30](catx-ex99_2s30.jpg)

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

------

![Slide 31](catx-ex99_2s31.jpg)

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

------

![Slide 32](catx-ex99_2s32.jpg)

Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

------

![Slide 33](catx-ex99_2s33.jpg)

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

------

![Slide 34](catx-ex99_2s34.jpg)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

------

![Slide 35](catx-ex99_2s35.jpg)

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

------

![Slide 36](catx-ex99_2s36.jpg)

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

------

![Slide 37](catx-ex99_2s37.jpg)

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

------

![Slide 38](catx-ex99_2s38.jpg)

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

------

![Slide 39](catx-ex99_2s39.jpg)

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

------

![Slide 40](catx-ex99_2s40.jpg)

------

![Slide 41](catx-ex99_2s41.jpg)

A Decade of Deliberate, End-to-End Engineering

------

![Slide 42](catx-ex99_2s42.jpg)

Built Over a Decade:

------

![Slide 43](catx-ex99_2s43.jpg)

------

![Slide 44](catx-ex99_2s44.jpg)

Abbreviations

------

![Slide 45](catx-ex99_2s45.jpg)

APPENDIX

------

![Slide 46](catx-ex99_2s46.jpg)

------

![Slide 47](catx-ex99_2s47.jpg)

NETs Trials

------

![Slide 48](catx-ex99_2s48.jpg)

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

------

![Slide 49](catx-ex99_2s49.jpg)

Refractory Metastatic Melanoma Trials

------

![Slide 50](catx-ex99_2s50.jpg)

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

------

![Slide 51](catx-ex99_2s51.jpg)

------

![Slide 52](catx-ex99_2s52.jpg)

------

![Slide 53](catx-ex99_2s53.jpg)

Construct designed for better clinical outcome

------

![Slide 54](catx-ex99_2s54.jpg)

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

------

![Slide 55](catx-ex99_2s55.jpg)

------

![Slide 56](catx-ex99_2s56.jpg)